Portal de Periódicos da CAPES

Mutant Metabolic Enzymes Are at the Origin of Gliomas

2009; American Association for Cancer Research; Volume: 69; Issue: 24 Linguagem: Inglês

10.1158/0008-5472.can-09-2650

1538-7445

Hai Yan, Darell D. Bigner, Victor E. Velculescu, D. Williams Parsons,

Glioma Diagnosis and Treatment

Mutations of the isocitrate dehydrogenase (IDH) metabolic enzymes IDH1 and IDH2 have been found to be frequent and early genetic alterations in astrocytomas and oligodendrogliomas. All mutations identified to date affect a single amino acid located within the isocitrate binding site (R132 of IDH1 and the analogous R172 residue of IDH2). IDH1 and IDH2 mutations define a specific subtype of gliomas and may have significant utility for the diagnosis, prognosis, and treatment of patients with these tumors.